Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial.

Background: IMpower010 (NCT02486718) demonstrated significantly improved disease-free survival (DFS) with adjuvant atezolizumab versus best supportive care (BSC) following platinum-based chemotherapy in the programmed death-ligand 1 (PD-L1)-positive and all stage II-IIIA non-small-cell lung cancer (NSCLC) populations, at the DFS interim analysis. Results of the first interim analysis of overall survival (OS) are reported here.

Patient And Methods: The design, participants, and primary-endpoint DFS outcomes have been reported for this phase III, open-label, 1 : 1 randomised study of atezolizumab (1200 mg q3w; 16 cycles) versus BSC after adjuvant platinum-based chemotherapy (1-4 cycles) in adults with completely resected stage IB (≥4 cm)-IIIA NSCLC (per the Union Internationale Contre le Cancer and American Joint Committee on Cancer staging system, 7th edition).

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.

Background: Novel adjuvant strategies are needed to optimise outcomes after complete surgical resection in patients with early-stage non-small-cell lung cancer (NSCLC). We aimed to evaluate adjuvant atezolizumab versus best supportive care after adjuvant platinum-based chemotherapy in these patients.

Methods: IMpower010 was a randomised, multicentre, open-label, phase 3 study done at 227 sites in 22 countries and regions.

[Analysis of plasma fibrinogen in evaluating the effectiveness and prognosis of polyradiomodifying therapy of malignant tumors of the upper respiratory tract].

Patients with malignant tumors of the upper respiratory tract showed higher concentrations of fibrinogen in plasma the level of which was correlated with the stage of disease. Measurements of the protein in the course of radiation therapy demonstrated that two months after effective treatment fibrinogen concentrations decreased to normal values and remained at that level throughout the remission time. If radiation therapy was ineffective, fibrinogen concentrations remained high during 2 to 4 months after exposure.

[Proteolysis and malignant growth (review)].

Modern data on participation of proteolytic enzymes from tissues and blood in malignant growth as well as their role in tumor invasiveness and metastatic spreading are reviewed. Alterations in content of the protein inhibitors of proteolysis occurred in tumors as well as diagnostic and prognostic significance of the inhibitors estimation in blood serum of oncological patients are considered. The experimental data on the antitumoral effect of native and synthetic inhibitors of proteolysis are discussed.

[Determination of papain activity].

A method is developed to determine the proteolytic activity of papain by the hydrolysis of protamine sulphate, a low-molecular weight protein rich in arginine. Sensitivity of the method is 20 times as high as sensitivity of the known methods for determination of the enzyme activity by the cleavage of hemoglobin and casein.